Table 1.
Baseline characteristics of new users of insulin in the quarter prior to commencing insulin therapy for all starters and for those with an HbA1c measurement at baseline and 12 months
| Parameter | Detemir | Glargine | NPH | Premix | Total |
|---|---|---|---|---|---|
| All insulin starters | |||||
| People, n (%) | 357 (4.5) | 2197 (27.4) | 1463 (18.3) | 3992 (49.8) | 8009 (100) |
| Age (years) | 58.9 ± 12.1 | 61.1 ± 12.2 | 60.7 ± 12.3 | 61.3 ± 11.6 | 61.0 ± 11.9 |
| Gender (% male) | 47.0 | 45.0 | 46.0 | 43.0 | 44.0 |
| Body weight (kg) | 87.8 ± 22.6 | 87.4 ± 18.8 | 88.1 ± 20.1 | 83.8 ± 18.6 | 85.4 ± 19.2 |
| Duration of diabetes (years) | 5.7 ± 4.9 | 6.2 ± 5.2 | 6.1 ± 5.5 | 6.0 ± 5.6 | 6.0 ± 5.5 |
| HbA1c (%)§ | 9.6 ± 1.7 | 9.5 ± 1.5 | 9.4 ± 1.6 | 9.5 ± 1.7 | 9.5 ± 1.6 |
| OGLDs prescribed, n* | 2.02 ± 0.65 | 2.01 ± 0.62 | 1.95 ± 0.63 | 1.92 ± 0.63 | 1.96 ± 0.63 |
| With HbA1c result at baseline and 12 months | |||||
| People, n (%)† | 114 (2.6) | 968 (22.3) | 727 (16.8) | 2528 (58.3) | 4337 |
| Age (years) | 58.4 ± 11.8 | 60.1 ± 11.7 | 59.8 ± 12.4 | 61.5 ± 11.2 | 60.8 ± 11.6 |
| Gender (% male) | 49.1 | 45.9 | 47.3 | 44.9 | 45.6 |
| Body weight (kg) | 84.9 ± 21.5 | 87.2 ± 18.9 | 87.8 ± 21.1 | 83.7 ± 18.6 | 85.3 ± 19.3 |
| Duration of diabetes (years) | 5.6 ± 4.7 | 6.4 ± 5.5 | 5.6 ± 4.7 | 6.2 ± 5.8 | 6.2 ± 5.6 |
| HbA1c (%) | 9.6 ± 1.7 | 9.5 ± 1.5 | 9.4 ± 1.6 | 9.5 ± 1.7 | 9.5 ± 1.6 |
| OGLDs prescribed, n‡ | 2.01 ± 0.65 | 2.03 ± 0.61 | 2.01 ± 0.65 | 1.93 ± 0.61 | 1.96 ± 0.62 |
Data expressed as mean ± SD unless indicated. Data on ethnic origin were not available. HbA1c, glycated haemoglobin; NPH, neutral protamine Hagedorn; OGLDs, oral glucose-lowering drugs.
Data for OGLDs based on data for 331 people on detemir, 2034 on glargine, 1215 on NPH and 3317 on premix.
Percentages relate to the proportion of patients in each group of the 4337 patients who had a HbA1c result at baseline and at 12 months.
Data for OGLDs based on data for 109 people starting detemir, 907 on glargine, 556 for NPH and 2528 for premix.
Data based on the 4337 patients who had a HbA1c result at baseline and at 12 months.